ECSP099793A - Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas - Google Patents

Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas

Info

Publication number
ECSP099793A
ECSP099793A EC2009009793A ECSP099793A ECSP099793A EC SP099793 A ECSP099793 A EC SP099793A EC 2009009793 A EC2009009793 A EC 2009009793A EC SP099793 A ECSP099793 A EC SP099793A EC SP099793 A ECSP099793 A EC SP099793A
Authority
EC
Ecuador
Prior art keywords
microparts
composition
prolonged release
somatostatin derivative
somatostatin
Prior art date
Application number
EC2009009793A
Other languages
English (en)
Inventor
Olivier Lambert
Marc Riemen-Schnitter
Vitomir Vucenovic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38222465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099793(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP099793A publication Critical patent/ECSP099793A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a micropartículas mejoradas que comprenden un análogo de somatostatina, a un proceso para la elaboración de estas micropartículas, y a composiciones farmacéuticas que las comprenden.
EC2009009793A 2007-05-24 2009-12-11 Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas ECSP099793A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07108796 2007-05-24

Publications (1)

Publication Number Publication Date
ECSP099793A true ECSP099793A (es) 2010-01-29

Family

ID=38222465

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009793A ECSP099793A (es) 2007-05-24 2009-12-11 Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas

Country Status (42)

Country Link
US (2) US20100178344A1 (es)
EP (2) EP3666263A1 (es)
JP (1) JP5507447B2 (es)
KR (2) KR101930588B1 (es)
CN (1) CN101677965B (es)
AR (1) AR066677A1 (es)
AU (1) AU2008252931B2 (es)
BR (1) BRPI0811904A2 (es)
CA (1) CA2683935C (es)
CL (1) CL2008001509A1 (es)
CO (1) CO6241097A2 (es)
CR (1) CR11078A (es)
CU (1) CU24028B1 (es)
DK (1) DK2164473T3 (es)
DO (1) DOP2009000262A (es)
EA (1) EA018203B1 (es)
EC (1) ECSP099793A (es)
ES (1) ES2761227T3 (es)
GE (1) GEP20125582B (es)
GT (1) GT200900302A (es)
HN (1) HN2009003296A (es)
HU (1) HUE046490T2 (es)
IL (1) IL201571B (es)
MA (1) MA31445B1 (es)
ME (1) ME00955B (es)
MX (1) MX2009012536A (es)
MY (1) MY148915A (es)
NI (1) NI200900207A (es)
NZ (1) NZ580589A (es)
PA (1) PA8781501A1 (es)
PE (1) PE20090387A1 (es)
PL (1) PL2164473T3 (es)
PT (1) PT2164473T (es)
SI (1) SI2164473T1 (es)
SM (1) SMP200900099B (es)
SV (1) SV2009003421A (es)
TN (1) TN2009000447A1 (es)
TW (1) TWI412373B (es)
UA (1) UA97396C2 (es)
UY (1) UY31103A1 (es)
WO (1) WO2008142153A1 (es)
ZA (1) ZA200907168B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
RU2403914C2 (ru) * 2009-03-27 2010-11-20 Федеральное государственное учреждение Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи (ФГУ МНИОИ им. П.А. Герцена Росмедтехнологий) Способ выбора тактики послеоперационного лечения медуллярного рака щитовидной железы
WO2012083026A1 (en) * 2010-12-15 2012-06-21 Evonik Degussa Corporation Branched polyol polyesters, blends and pharmaceutical formulations comprising same
HUE046004T2 (hu) 2011-04-25 2020-01-28 Shan Dong Luye Pharm Co Ltd Risperidon nyújtott hatóanyagleadású mikroszféra készítmény
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
ES2834318T3 (es) * 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
US10821200B2 (en) 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
EP3339372A1 (en) * 2016-12-22 2018-06-27 Solvay SA Glycolic acid polymer composition
CN110870853B (zh) * 2018-08-29 2020-12-11 深圳翰宇药业股份有限公司 缓释帕瑞肽微球及其制备方法
US20210290609A1 (en) * 2018-12-04 2021-09-23 Vanda Pharmaceuticals Inc. Depot administration of iloperidone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
FI106926B (fi) * 1989-07-07 2001-05-15 Novartis Ag Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
CA2316052C (en) * 1989-07-07 2008-09-02 David Bodmer Sustained release formulations of water soluble peptides
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
EP1240896A3 (en) 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
CN1905895A (zh) * 2003-11-25 2007-01-31 诺瓦提斯公司 促生长素抑制素类似物治疗功效的生物标志

Also Published As

Publication number Publication date
DK2164473T3 (da) 2019-12-16
GT200900302A (es) 2011-07-01
EP3666263A1 (en) 2020-06-17
KR101930588B1 (ko) 2018-12-18
CU20090200A7 (es) 2011-09-21
IL201571A0 (en) 2010-05-31
US9351923B2 (en) 2016-05-31
PE20090387A1 (es) 2009-04-28
PA8781501A1 (es) 2008-12-18
CA2683935C (en) 2016-07-19
UA97396C2 (ru) 2012-02-10
CR11078A (es) 2009-12-04
NI200900207A (es) 2010-09-07
SI2164473T1 (sl) 2020-02-28
HUE046490T2 (hu) 2020-03-30
TW200906437A (en) 2009-02-16
US20100178344A1 (en) 2010-07-15
SMP200900099B (it) 2010-11-12
ZA200907168B (en) 2010-07-28
BRPI0811904A2 (pt) 2014-11-18
ME00955B (me) 2012-06-20
PL2164473T3 (pl) 2020-07-27
UY31103A1 (es) 2009-01-05
EP2164473A1 (en) 2010-03-24
CO6241097A2 (es) 2011-01-20
TWI412373B (zh) 2013-10-21
CU24028B1 (es) 2014-10-02
US20130129798A1 (en) 2013-05-23
KR20100017904A (ko) 2010-02-16
AU2008252931A1 (en) 2008-11-27
SV2009003421A (es) 2010-05-21
DOP2009000262A (es) 2010-10-15
EP2164473B1 (en) 2019-09-11
MA31445B1 (fr) 2010-06-01
EA200901523A1 (ru) 2010-04-30
SMAP200900099A (it) 2010-01-19
CL2008001509A1 (es) 2009-05-08
CN101677965A (zh) 2010-03-24
CN101677965B (zh) 2015-09-09
KR20160002937A (ko) 2016-01-08
TN2009000447A1 (en) 2011-03-31
JP5507447B2 (ja) 2014-05-28
CA2683935A1 (en) 2008-11-27
IL201571B (en) 2018-11-29
NZ580589A (en) 2011-12-22
MX2009012536A (es) 2009-12-03
GEP20125582B (en) 2012-07-25
PT2164473T (pt) 2019-12-11
JP2010527971A (ja) 2010-08-19
MY148915A (en) 2013-06-14
HN2009003296A (es) 2014-02-10
AR066677A1 (es) 2009-09-02
WO2008142153A1 (en) 2008-11-27
EA018203B1 (ru) 2013-06-28
ES2761227T3 (es) 2020-05-19
AU2008252931B2 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
ECSP099793A (es) Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
BRPI0909820A2 (pt) Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
PH12013502192A1 (en) Antibodies against human angiopoietin 2
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
GT201400111A (es) Triazolopiridinas sustituidas
ECSP10010295A (es) Formulacion de anticuerpo
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BR112015011430A2 (pt) composição para liberação imediata e prolongada
ES2465478T8 (es) Composiciones farmacéuticas que comprenden brivaracetam
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
BRPI0916936A2 (pt) composições faramacêuticas e métodos para produzir baixas concentrações de impureza da mesmas.
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
PT2362778T (pt) Composições que compreendem vitamina c
BR112016007031A8 (pt) composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida
ECSP10010360A (es) Composicion farmaceutica
GT200800254A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparacion, composiciones que las contienen y utilizacion.
UY31002A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona